共 50 条
- [21] Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell LymphomaNEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (06): : 507 - 516Wang, Michael L.Rule, SimonMartin, PeterGoy, AndreAuer, RebeccaKahl, Brad S.Jurczak, WojciechAdvani, Ranjana H.Romaguera, Jorge E.Williams, Michael E.Barrientos, Jacqueline C.Chmielowska, EwaRadford, JohnStilgenbauer, StephanDreyling, MartinJedrzejczak, Wieslaw WiktorJohnson, PeterSpurgeon, Stephen E.Li, LeiZhang, LiangNewberry, KateOu, ZhishuoCheng, NancyFang, BingliangMcGreivy, JesseClow, FongBuggy, Joseph J.Chang, Betty Y.Beaupre, Darrin M.Kunkel, Lori A.Blum, Kristie A.
- [22] Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed/refractory Waldenstrom macroglobulinemiaBRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 109 - 110Lewis, David JohnPalomba, M. LiaPatel, Manish R.Eyre, Toby A.Jurczak, WojciechGastinne, ThomasMa, ShuoCohen, Jonathon B.Patel, KrishBrown, Jennifer R.Scarfo, LydiaMunir, TalhaLech-Maranda, EwaHoffmann, Marc S.Ujjani, Chaitra S.Fakhri, BitaWang, MichaelIzutsu, KojiNagai, HirokazuTam, Constantine S.Seymour, John F.Rhodes, Joanna M.Vose, JulieMcKinney, MatthewGerson, James N.Barve, Minal A.Kuss, BryoneKoh, YoungilGao, WeiRuppert, Amy S.Walgren, Richard A.Tsai, Donald E.Nair, BinojBao, KatherineMato, Anthony R.Cheah, Chan Y.
- [23] Outcomes of pirtobrutinib for relapsed/refractory mantle cell lymphoma in compassionate use program in EuropeCANCER MEDICINE, 2024, 13 (10):Aydilek, EnverWulf, GeraldSchwarz, FriedrichBacher, UlrikeRummel, MathiasStiefel, OlgaKerkhoff, AndreaMaulhardt, MarkusMelchardt, ThomasPabst, ThomasLenz, GeorgShumilov, Evgenii
- [24] Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory (R/R) mantle cell lymphoma (MCL).JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Epperla, NarendranathHamadani, MehdiAhn, Kwang WooOak, EunhyeCashen, Amanda F.Kanate, Abraham SebastianCalzada, OscarFarmer, Zachary LukeTallarico, MichaelNabhan, ChadiCosta, Luciano J.Kenkre, Vaishalee PadgaonkarGhosh, NilanjanCohen, Jonathon BrettHari, ParameswaranFenske, Timothy S.
- [25] Genomic evolution and resistance to pirtobrutinib in covalent BTK-inhibitor pre-treated chronic lymphocytic leukemia patients: results from the phase I/II BRUIN StudyLEUKEMIA & LYMPHOMA, 2023, 64 : S25 - S26Brown, JenniferDesikan, Sai PrasadNguyen, BastienWon, HelenTantawy, Shady I.McNeely, Samuel C.Marella, NarasimhaEbata, KevinWoyach, JenniferPatel, KrishTam, Constantine S.Eyre, Toby A.Cheah, Chan Y.Shah, NiravGhia, PaoloJurczak, WojciechBalbas, MinnaNair, BinojAbada, PaoloWang, ChunxiaoWang, DeniseMato, AnthonyGandhi, VarshaWierda, William
- [26] Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell LymphomaJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (24) : 3988 - +Wang, Michael L.Jurczak, WojciechZinzani, Pier LuigiEyre, Toby A.Cheah, Chan Y.Ujjani, Chaitra S.Koh, YoungilIzutsu, KojiGerson, James N.Flinn, IanTessoulin, BenoitAlencar, Alvaro J.Ma, ShuoLewis, DavidLech-Maranda, EwaRhodes, JoannaPatel, KrishMaddocks, KamiLamanna, NicoleWang, YucaiTam, Constantine S.Munir, TalhaNagai, HirokazuHernandez-Ilizaliturri, FranciscoKumar, AnitaFenske, Timothy S.Seymour, John F.Zelenetz, Andrew D.Nair, BinojTsai, Donald E.Balbas, MinnaWalgren, Richard A.Abada, PaoloWang, ChunxiaoZhao, JunjieMato, Anthony R.Shah, Nirav N.
- [27] Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Shah, Nirav NiranjanJurczak, WojciechZinzani, Pier LuigiEyre, Toby A.Cheah, ChanUjjani, Chaitra ShankarIzutsu, KojiMa, ShuoFlinn, Ian W.Alencar, Alvaro JoseLewis, David JohnPatel, KrishMaddocks, Kami J.Wang, YucaiMunir, TalhaZelenetz, Andrew DavidBalbas, MinnaTsai, Donald E.Wang, ChunxiaoWang, Michael
- [28] Genomic Evolution and Resistance during Pirtobrutinib Therapy in Covalent BTK-Inhibitor (cBTKi) Pre-Treated Chronic Lymphocytic Leukemia Patients: Updated Analysis from the BRUIN StudyBLOOD, 2023, 142Brown, Jennifer R.Desikan, Sai PrasadNguyen, BastienWon, HelenTantawy, Shady I.McNeely, SamuelMarella, NarasimhaEbata, KevinWoyach, Jennifer A.Patel, KrishTam, Constantine S.Eyre, Toby A.Cheah, Chan Y.Shah, Nirav N.Ghia, PaoloJurczak, WojciechBalbas, MinnaNair, BinojAbada, PaoloWang, ChunxiaoWang, YingRoeker, Lindsey E.Gandhi, VarshaWierda, William G.
- [29] Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma: Results from the Phase 1/2 BRUIN StudyBLOOD, 2023, 142Shah, Nirav N.Zinzani, Pier LuigiWang, Michael L.Nasta, Sunita D.Lech-Maranda, EwaOgawa, YoshiakiFakhri, BitaKuss, BryoneMiyashita, KanamePatel, KrishCoombs, Catherine C.Ma, ShuoPatel, ManishBarve, Minal A.Tessoulin, BenoitStathis, AnastasiosKim, Won SeogEnnishi, DaisukeHashimoto, DaigoKojima, KensukeZelenetz, Andrew D.Cohen, Jonathon B.Vose, Julie M.Maddocks, Kami J.Munir, TalhaSun, FangfangBian, FaithTsai, Donald E.Abada, PaoloCheah, Chan Y.
- [30] Pirtobrutinib, A Highly Selective, Non-covalent (Reversible) BTK Inhibitor In Previously Treated Mantle Cell Lymphoma: Updated Results From The Phase 1/2 BRUIN StudyBRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 101 - 104Wang, MichaelShah, NiravAlencar, AlvaroGerson, JamesPatel, ManishFakhri, BitaJurczak, WojciechTan, XuanLewis, KatharineFenske, TimothyCoombs, CatherineFlinn, IanLewis, DavidLe Gouill, StevenPalomba, M. LiaWoyach, JenniferPagel, JohnLamanna, NicoleCohen, JohnathonBarve, MinalGhia, PaoloEyre, TobyZinzani, Pier LuigiUjjani, ChaitraKoh, YoungilIzutsu, KojiLech-Maranda, EwaTam, ConstantineSundaram, SuchitraYin, MingNair, BinojTsai, DonaldBalbas, MinnaMato, AnthonyCheah, Chan